{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:51:44Z","timestamp":1786121504530,"version":"build-2736575974"},"reference-count":152,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009881","name":"Breakthrough T1D Canada","doi-asserted-by":"publisher","award":["3-COE-2022-1103-M-B"],"award-info":[{"award-number":["3-COE-2022-1103-M-B"]}],"id":[{"id":"10.13039\/100009881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032489","name":"Breakthrough T1D Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-189977"],"award-info":[{"award-number":["PJT-189977"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-154304"],"award-info":[{"award-number":["FDN-154304"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:10:48Z","timestamp":1779808248000},"page":"4407-4421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering human T cells with antigen receptors for immune regulation in autoimmune disease and transplantation"],"prefix":"10.1016","volume":"34","author":[{"given":"Sonya","family":"Mangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoliina","family":"Tuomela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-5790","authenticated-orcid":false,"given":"Megan K.","family":"Levings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.017_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2021.11.007","article-title":"Emerging strategies for treating autoimmune disorders with genetically modified Treg cells","volume":"149","author":"Boardman","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of Regulatory T Cell Development by the Transcription Factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.017_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-024-01089-x","article-title":"Harnessing the biology of regulatory T cells to treat disease","volume":"24","author":"Wardell","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.017_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166135","article-title":"Opportunities for Treg cell therapy for the treatment of human disease","volume":"14","author":"Bluestone","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.05.017_bib7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In Vitro\u2013expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib8","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1172\/JCI33185","article-title":"Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice","volume":"118","author":"Tsang","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.017_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2006-05-025460","article-title":"In vitro\u2013expanded donor alloantigen\u2013specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance","volume":"109","author":"Golshayan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.166.2.973","article-title":"Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question","volume":"166","author":"Suchin","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib11","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1111\/ajt.12433","article-title":"Clinical Grade Manufacturing of Human Alloantigen-Reactive Regulatory T Cells for Use in Transplantation","volume":"13","author":"Putnam","year":"2013","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.ajt.2023.06.012","article-title":"Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial","volume":"23","author":"Guinan","year":"2023","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2628","article-title":"Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans","volume":"14","author":"Tang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajt.2024.09.009","article-title":"Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation","volume":"25","author":"Kurt","year":"2025","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-024-45056-x","article-title":"Smith-specific regulatory T cells halt the progression of lupus nephritis","volume":"15","author":"Eggenhuizen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1716","article-title":"Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103327","article-title":"Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy","volume":"149","author":"Tewari","year":"2024","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib20","article-title":"Emerging Strategies in TCR-Engineered T Cells","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.171844","article-title":"GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes","volume":"9","author":"Uenishi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.02.028","article-title":"Dual CD8 and TCR editing in regulatory T cells mediates HLA-A2-restricted tissue-specific homing","author":"Porret","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","article-title":"Genetics of the HLA Region in the Prediction of Type 1 Diabetes","volume":"11","author":"Noble","year":"2011","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.ymthe.2026.05.017_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.017_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104220","article-title":"Building a CAR-Treg: Going from the basic to the luxury model","volume":"358","author":"Rosado-S\u00e1nchez","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz3866","article-title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","volume":"12","author":"Dawson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.017_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib29","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/ajt.15787","article-title":"Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients","volume":"20","author":"Sicard","year":"2020","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib31","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/ajt.17063","article-title":"Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival","volume":"22","author":"Wagner","year":"2022","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp6519","article-title":"CAR Treg cells mediate linked suppression and infectious tolerance in islet transplantation in mice","volume":"17","author":"Wardell","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188624","article-title":"CAR Treg synergy with anti-CD154 promotes infectious tolerance and dictates allogeneic heart transplant acceptance","volume":"10","author":"Durgam","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajt.2025.07.589","article-title":"STEADFAST Study Update: A Phase 1\/2 Clinical Trial of Regulatory T Cells Expressing a Chimeric Antigen Receptor Directed Towards HLA-A2 in Renal Transplantation","volume":"25","author":"Schreeb","year":"2025","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib37","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/S0168-8278(25)01154-7","article-title":"QEL-001 LIBERATE Study Expansion Cohort CAR-Treg engraftment and expansion following rATG conditioning in liver transplantation. European Association for the Study of the Liver","volume":"82","author":"Sanchez-Fueyo","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ymthe.2026.05.017_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib40","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1207108","article-title":"Regulatory T cells targeting a pathogenic MHC class II: Insulin peptide epitope postpone spontaneous autoimmune diabetes","volume":"14","author":"Obarorakpor","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib42","article-title":"Insulin B peptide-MHC class II-specific chimeric antigen receptor-Tregs prevent autoimmune diabetes in mice","volume":"133","author":"Spanier","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.017_bib43","article-title":"ENTPD3-specific CAR Regulatory T cells for Local Immune Control in T1D","author":"Pieper","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.05.017_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160674","article-title":"Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses","volume":"7","author":"Bolivar-Wagers","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3390\/cells14171318","article-title":"Human CAR Tregs Targeting SOD1 and Expressing BDNF Reduce Inflammation and Delay Disease in G93A hSOD1-NSG Mice","volume":"14","author":"Graber","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.05.017_bib48","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3390\/cells12162115","article-title":"Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer\u2019s Disease","volume":"12","author":"Saetzler","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2026.05.017_bib49","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/CIRCULATIONAHA.125.076321","article-title":"Engineered Regulatory T Lymphocytes Promote Infarcted Heart Repair","volume":"153","author":"Zhang","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2026.05.017_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9331","article-title":"Human OX40L\u2013CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity","volume":"16","author":"Rui","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jcyt.2024.12.015","article-title":"CXCR5-targeted chimeric antigen receptor T regulatory cells for the selective inhibition of follicular helper T cell and B cell interaction","volume":"27","author":"Murai","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.05.017_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208436119","article-title":"Biosensors for inflammation as a strategy to engineer regulatory T cells for cell therapy","volume":"119","author":"Bittner","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.017_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114994","article-title":"Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells","volume":"43","author":"Barra","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.05.017_bib54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92865","article-title":"T cells expressing chimeric antigen receptor promote immune tolerance","volume":"2","author":"Pierini","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib55","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib56","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.ymthe.2026.05.017_bib58","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib59","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib60","article-title":"Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41573-025-01349-4","article-title":"Roads and detours for CAR T cell therapy in autoimmune diseases","volume":"25","author":"Avouac","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.017_bib62","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib63","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.017_bib65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tan.15146","article-title":"Chimeric HLA antibody receptor T cells to target HLA -specific B cells in solid organ transplantation","volume":"102","author":"Gille","year":"2023","journal-title":"HLA"},{"key":"10.1016\/j.ymthe.2026.05.017_bib66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/tan.15156","article-title":"Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation","volume":"102","author":"Betriu","year":"2023","journal-title":"HLA"},{"key":"10.1016\/j.ymthe.2026.05.017_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601385","article-title":"Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients","volume":"16","author":"Valent\u00edn-Quiroga","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib68","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2025-276","article-title":"First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"146","author":"Salhotra","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib69","article-title":"A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy [abstract]","volume":"77 (suppl 9)","author":"Kohler","year":"2025","journal-title":"Am. Congress Rhematol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib70","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib71","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.ymthe.2021.04.034","article-title":"CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII","volume":"29","author":"Rana","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib72","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2025.01.045","article-title":"Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer","volume":"33","author":"Du","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib73","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib74","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/nm1676","article-title":"T cell\u2013encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib76","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib77","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib78","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib79","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/eji.202048934","article-title":"Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive","volume":"51","author":"Mohseni","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adx7845","article-title":"Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function","volume":"11","author":"Boardman","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.05.017_bib81","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.ymthe.2026.02.001","article-title":"CAR-mediated release of IL-10 increases the function of regulatory T cells: relevance for future clinical application","volume":"34","author":"Saleem","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib82","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","article-title":"Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces","volume":"28","author":"Rubtsov","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.05.017_bib83","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1053\/j.gastro.2019.09.002","article-title":"Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells","volume":"157","author":"Cook","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2026.05.017_bib84","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/mt.2012.71","article-title":"Enforced IL-10 Expression Confers Type 1 Regulatory T Cell (Tr1) Phenotype and Function to Human CD4+ T Cells","volume":"20","author":"Andolfi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib85","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ymthe.2017.06.029","article-title":"IL-10-Engineered Human CD4+ Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism","volume":"25","author":"Locafaro","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib86","first-page":"S6","article-title":"Off-the-Shelf Engineered Tr1 Cells (TRX103) in Patients with Hematological Malignancies Undergoing HLA-Mismatched Hematopoietic Cell Transplantation (HCT) Show Safety and Dose Dependent Effects","volume":"32","author":"Malki","year":"2026","journal-title":"Transpl. Cell. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4237","article-title":"Programming tissue-sensing T cells that deliver therapies to the brain","volume":"386","author":"Simic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.017_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4793","article-title":"Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs","volume":"386","author":"Reddy","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.017_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103057","article-title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","volume":"138","author":"Henschel","year":"2023","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139991","article-title":"Selective expansion of regulatory T cells using an orthogonal IL-2\/IL-2 receptor system facilitates transplantation tolerance","volume":"131","author":"Hirai","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.017_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1005582","article-title":"Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors","volume":"13","author":"Kremer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib92","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.ymthe.2023.04.021","article-title":"A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells","volume":"31","author":"Cook","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib93","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.ymthe.2023.07.016","article-title":"Dual-locus, dual-HDR editing permits efficient generation of antigen-specific regulatory T cells with robust suppressive activity","volume":"31","author":"Hunt","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib94","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41467-025-57681-1","article-title":"Redirecting immune signaling with cytokine adaptors","volume":"16","author":"Abhiraman","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib95","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41586-025-09393-1","article-title":"Expanding the cytokine receptor alphabet reprograms T cells into diverse states","volume":"645","author":"Zhao","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.017_bib96","author":"Tang"},{"key":"10.1016\/j.ymthe.2026.05.017_bib97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.1402381","article-title":"Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226","volume":"195","author":"Fuhrman","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib98","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2337\/db23-0307","article-title":"Treg-Specific CD226 Deletion Reduces Diabetes Incidence in NOD Mice by Improving Regulatory T-Cell Stability","volume":"72","author":"Thirawatananond","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.ymthe.2026.05.017_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1698442","article-title":"Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101385","article-title":"High-affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells","volume":"32","author":"Cochrane","year":"2024","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.05.017_bib101","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1158\/0008-5472.CAN-09-2824","article-title":"A High Molecular Weight Melanoma-Associated Antigen\u2013Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas","volume":"70","author":"Burns","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.017_bib102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2019-131024","article-title":"Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy","volume":"134","author":"Singh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib104","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane","volume":"180","author":"James","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib106","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib107","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126194","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function","volume":"4","author":"Boroughs","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167215","article-title":"Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection","volume":"8","author":"Rosado-S\u00e1nchez","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.017_bib109","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib110","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib111","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymthe.2026.05.017_bib113","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib114","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR T cells","volume":"24","author":"Velasco C\u00e1rdenas","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","article-title":"Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib116","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","article-title":"CRISPR\/Cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2026.05.017_bib117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.017_bib118","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of \u03b6-deficient CARs into the CD3\u03b6 gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib119","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib121","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib122","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3390\/molecules28031482","article-title":"Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with 89Zr-oxine for Medium-Term In Vivo Cell Tracking","volume":"28","author":"Jacob","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2026.05.017_bib123","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3389\/fimmu.2020.00611","article-title":"Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood","volume":"11","author":"Motwani","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/ajt.13456","article-title":"Discarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells","volume":"16","author":"Dijke","year":"2016","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2026.05.017_bib125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood\u2013derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib126","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400249","article-title":"Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS","volume":"4","author":"Shneider","year":"2025","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ymthe.2026.05.017_bib127","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300362","article-title":"Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes","volume":"3","author":"Kadia","year":"2024","journal-title":"NEJM Evid."},{"key":"10.1016\/j.ymthe.2026.05.017_bib128","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/eji.202048949","article-title":"Isolation and expansion of thymus-derived regulatory T cells for use in pediatric heart transplant patients","volume":"51","author":"Romano","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib129","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jcyt.2022.06.006","article-title":"Consequences of adjusting cell density and feed frequency on serum-free expansion of thymic regulatory T cells","volume":"24","author":"MacDonald","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.05.017_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.893576","article-title":"A Novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic Tissue to Be Employed as Cellular Therapy","volume":"13","author":"Bernaldo-de-Quir\u00f3s","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib131","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231045","article-title":"First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant","volume":"220","author":"Bernaldo-de-Quir\u00f3s","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib132","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/j.jcyt.2024.03.339","article-title":"Thymus-derived regulatory T cells as a universal off-the-shelf anti-inflammatory therapy: technology transfer in preparation for a phase 1 clinical trial","volume":"26","author":"Ivison","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.05.017_bib133","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.stem.2025.12.010","article-title":"Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells","volume":"33","author":"Jones","year":"2026","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib134","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.stem.2024.05.004","article-title":"Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors control GvHD in a xenograft model","volume":"31","author":"Yano","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib135","doi-asserted-by":"crossref","DOI":"10.1093\/stmcls\/sxaf001","article-title":"A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCs","volume":"43","author":"Fong","year":"2025","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2026.05.017_bib136","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/bloodadvances.2022009619","article-title":"Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS","volume":"7","author":"Gladstone","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.05.017_bib137","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.05.017_bib138","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1038\/s41467-025-64945-3","article-title":"HLA matching or CRISPR editing of HLA class I\/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model","volume":"16","author":"McCallion","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.017_bib139","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.017_bib140","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.05.017_bib141","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.05.017_bib142","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.ymthe.2026.05.017_bib143","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.017_bib144","first-page":"5702","article-title":"Combining T-cell\u2013specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.017_bib145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2026.05.017_bib146","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib147","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.017_bib148","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2026.05.017_bib149","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41586-026-10235-x","article-title":"In vivo site-specific engineering to reprogram T cells","volume":"652","author":"Nyberg","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.017_bib150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.05.017_bib151","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.017_bib152","article-title":"Antigen-specific T cell immunotherapy by in vivo mRNA delivery","author":"Su","year":"2024","journal-title":"bioRxiv"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:46:48Z","timestamp":1786078008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":152,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626004041"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering human T cells with antigen receptors for immune regulation in autoimmune disease and transplantation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}